An Indiana University School of Medicine study produced a potential biomarker for chemotherapy-induced cardiotoxicity in breast cancer patients. The researchers also identified a drug that may work to minimize cardiotoxicity.
In a study from the Johns Hopkins Kimmel Cancer Center, researchers described a novel mechanism of tumor formation in kidney cancers driven by overexpression of the mechanistic target of rapamycin complex 1 signaling pathway with loss of the tuberous sclerosis complex tumor suppressor gene.
Four-year follow-up results from the phase III GLOW study showed that investigational, fixed-duration treatment with Imbruvica (ibrutinib) in combination with venetoclax reduced the risk of progression or death by 79% among older and/or unfit patients with previously untreated chronic lymphocytic leukemia compared to patients treated with chemoimmunotherapy.
Data from the phase III MAIA of Darzalex (daratumumab) in combination with lenalidomide and dexamethasone in newly diagnosed, transplant-ineligible patients with multiple myeloma—regardless of patients’ age and across clinically important subgroups, as well as health-related quality of life among frail TIE patients—were presented in oral and poster presentations at the American Society of Hematology 2022 Annual Meeting.
Positive initial data from a pivotal phase II expansion cohort evaluating investigational linvoseltamab (BCMAXCD3, formerly REGN5458) at the 200 mg dose recommended for further development in patients with heavily pre-treated, relapsed/refractory multiple myeloma, were presented at the 64th American Society of Hematology Annual Meeting and Exposition.
Positive new and updated data from a phase I and pivotal phase II trial (ELM-1 and ELM-2), evaluating investigational odronextamab in patients with relapsed/refractory diffuse large B-cell lymphoma, were presented in an oral session at the 64th American Society of Hematology Annual Meeting and Exposition and will form the basis of planned submissions to regulatory authorities in 2023, including to FDA.
Results from the RIGHT Choice phase II trial showed that Kisqali (ribociclib) plus endocrine therapy demonstrated a nearly one-year PFS benefit for patients with aggressive breast cancer.
Detailed results from the CAPItello-291 phase III trial showed AstraZeneca’s capivasertib in combination with Faslodex (fulvestrant) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival versus placebo plus Faslodex in patients with hormone receptor-positive, human epidermal growth factor receptor 2-low or negative, locally advanced or metastatic breast cancer, following recurrence or progression on, or after, endocrine therapy (with or without a CDK4/6 inhibitor).
Retrospective analyses of data from the Suppression of Ovarian Function Trial trial, led by Hologic Inc. and its subsidiary, Biotheranostics Inc., showed that the Breast Cancer Index test identified which premenopausal patients with early-stage, hormone-receptor positive breast cancer benefited from the addition of ovarian function suppression to primary adjuvant endocrine therapy.
A study published today by researchers at Fox Chase Cancer Center suggests that independent of demographic factors like socioeconomic status and access to healthcare, race itself may predict disparate outcomes between patients.
